Search: onr:"swepub:oai:DiVA.org:uu-197809" >
Reduced intensity c...
Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era
- Article/chapterEnglish2012
Publisher, publication year, extent ...
-
American Society of Hematology,2012
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-197809
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-197809URI
-
https://doi.org/10.1182/blood-2012-02-409763DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:124788654URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Tyrosine kinase inhibitors (TKIs) and reduced intensity conditioning (RIC)/nonmyeloablative (NMA) conditioning hematopoietic cell transplants (HCTs) have changed the therapeutic strategy for chronic myelogenous leukemia (CML) patients. We analyzed post-HCT outcomes of 306 CML patients reported to the Center for International Blood and Marrow Transplant Research aged 40 years and older undergoing RIC/NMA HCT from 2001 to 2007: 117 (38%) aged 40 to 49 years, 119 (39%) 50 to 59 years, and 70 (23%) 60 years or older. The majority (74%) had treatment with imatinib before HCT. At HCT, most patients aged 40 to 49 years were in chronic phase (CP) 1 (74%), compared with 31% aged 60 years or older. Siblings were donors for 56% aged 40 to 49 years; older cohorts had more unrelated donors. The majority received peripheral blood grafts and RIC across all age groups. 3 year overall survival (54%, 52%, and 41%), day + 100 grade II-IV acute GVHD (26%, 32%, and 32%), chronic GVHD (58%, 51%, and 43%), and 1-year treatment-related mortality (18%, 20%, and 13%) were similar across ages. The 3-year relapse incidence (36%, 43%, and 66%) and disease-free survival (35%, 32%, and 16%) were inferior in the oldest cohort. Importantly, for CP1 patients, relapse and disease-free survival were similar across age cohorts. Allogeneic RIC HCT for older patients with CML can control relapse with acceptable toxicity and survival in TKI-exposed CML, especially if still in CP1.
Added entries (persons, corporate bodies, meetings, titles ...)
-
Ahn, Kwang Woo
(author)
-
Pedersen, Tanya L
(author)
-
Artz, Andrew
(author)
-
de Lima, Marcos
(author)
-
Pulsipher, Michael
(author)
-
Akpek, Gorgun
(author)
-
Aljurf, Mahmoud
(author)
-
Cahn, Jean-Yves
(author)
-
Cairo, Mitchell
(author)
-
Chen, Yi-Bin
(author)
-
Cooper, Brenda
(author)
-
Deol, Abhinav
(author)
-
Giralt, Sergio
(author)
-
Gupta, Vikas
(author)
-
Khoury, H Jean
(author)
-
Kohrt, Holbrook
(author)
-
Lazarus, Hillard M
(author)
-
Lewis, Ian
(author)
-
Olsson, RichardKarolinska Institutet
(author)
-
Pidala, Joseph
(author)
-
Savani, Bipin N
(author)
-
Seftel, Matthew
(author)
-
Socié, Gerard
(author)
-
Tallman, Martin
(author)
-
Ustun, Celaettin
(author)
-
Vij, Ravi
(author)
-
Vindeløv, Lars
(author)
-
Weisdorf, Daniel
(author)
-
Karolinska Institutet
(creator_code:org_t)
Related titles
-
In:Blood: American Society of Hematology119:17, s. 4083-40900006-49711528-0020
Internet link
Find in a library
-
Blood
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Warlick, Erica
-
Ahn, Kwang Woo
-
Pedersen, Tanya ...
-
Artz, Andrew
-
de Lima, Marcos
-
Pulsipher, Micha ...
-
show more...
-
Akpek, Gorgun
-
Aljurf, Mahmoud
-
Cahn, Jean-Yves
-
Cairo, Mitchell
-
Chen, Yi-Bin
-
Cooper, Brenda
-
Deol, Abhinav
-
Giralt, Sergio
-
Gupta, Vikas
-
Khoury, H Jean
-
Kohrt, Holbrook
-
Lazarus, Hillard ...
-
Lewis, Ian
-
Olsson, Richard
-
Pidala, Joseph
-
Savani, Bipin N
-
Seftel, Matthew
-
Socié, Gerard
-
Tallman, Martin
-
Ustun, Celaettin
-
Vij, Ravi
-
Vindeløv, Lars
-
Weisdorf, Daniel
-
show less...
- Articles in the publication
-
Blood
- By the university
-
Uppsala University
-
Karolinska Institutet